文献速递细菌感染、耐药与抗菌药物

Aptima生殖支原体检测在丹麦、挪威和瑞典的临床与分析性能评价

Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016.
PubMed 文献 · Clin Microbiol Infect · 2017-09-18

研究在2016年2月至2017年2月纳入丹麦、挪威和瑞典三家性病门诊的5269例连续就诊者,评估CE/IVD Aptima生殖支原体检测的临床与分析性能,并调查生殖支原体、沙眼衣原体和淋病奈瑟菌的流行率及生殖支原体对阿奇霉素和莫西沙星的耐药突变。结果显示生殖支原体流行率为7.2%,阿奇霉素耐药突变率为41.4%,莫西沙星耐药突变率为6.6%,两种TMA检测敏感性均显著优于mgpB qPCR。

要点

  • CE/IVD Aptima MG检测敏感性达99.13-100%,显著优于mgpB qPCR的73.24-81.60%。
  • 生殖支原体流行率为7.2%,阿奇霉素耐药突变率高达41.4%。
  • 莫西沙星耐药突变率为6.6%,多重耐药率为2.7%。

核心结论

  • 两种基于TMA的生殖支原体检测敏感性显著优于mgpB qPCR。
  • 生殖支原体流行率及阿奇霉素耐药率均较高。
  • 经验证且质量保证的分子检测、常规耐药检测和耐药监测至关重要。

研究设计与样本

  • 2016年2月至2017年2月,在丹麦、挪威和瑞典三家性病门诊连续纳入5269例就诊者。
  • 采用CE/IVD Aptima MG、MG Alt TMA-1、Aptima Combo 2和mgpB qPCR检测泌尿生殖道及生殖外标本(仅丹麦)。
  • 通过测序确定耐药相关突变,并测试不同浓度的生殖支原体及其他支原体菌株。

主要发现

  • 生殖支原体总流行率为7.2%(382/5269),各国为4.9-9.8%。
  • CE/IVD AMG、MG Alt TMA-1和mgpB qPCR的敏感性分别为99.13-100%、99.13-100%和73.24-81.60%。
  • CE/IVD AMG、MG Alt TMA-1和mgpB qPCR的特异性分别为99.57-99.96%、100%和99.69-100%。
  • 阿奇霉素耐药相关突变率为41.4%(120/290;各国17.7-56.6%)。
  • 莫西沙星耐药相关突变率为6.6%(18/274;各国4.1-10.2%),多重耐药率为2.7%(各国1.1-4.2%)。

关键数值与推荐

  • CE/IVD Aptima MG检测敏感性为99.13-100%,特异性为99.57-99.96%。
  • mgpB qPCR敏感性为73.24-81.60%,特异性为99.69-100%。
  • 阿奇霉素耐药突变率为41.4%(120/290),莫西沙星耐药突变率为6.6%(18/274),多重耐药率为2.7%。

临床怎么用

  • 优先选择敏感性高的TMA-based生殖支原体分子检测。
  • 对生殖支原体阳性样本开展常规阿奇霉素和莫西沙星耐药检测。
  • 加强生殖支原体抗菌药物耐药监测以指导治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mycoplasma genitalium (MG) causes urethritis and cervicitis, potentially causing reproductive complications. Resistance in MG to first-line (azithromycin) and second-line (moxifloxacin) treatment has increased. We examined the clinical and analytical performance of the new Conformité Européene (CE)/in vitro diagnostics (IVD) Aptima Mycoplasma genitalium assay (CE/IVD AMG; Hologic); the prevalence of MG, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG); and MG resistance to azithromycin and moxifloxacin in Denmark, Norway and Sweden in 2016. METHODS: From February 2016 to February 2017, urogenital and extragenital (only in Denmark) specimens from consecutive attendees at three sexually transmitted disease clinics were tested with the CE/IVD AMG, the research-use-only MG Alt TMA-1 assay (Hologic), Aptima Combo 2 (CT/NG) assay and a laboratory-developed TaqMan real-time mgpB quantitative real-time PCR (qPCR). Resistance-associated mutations were determined by sequencing. Strains of MG and other mycoplasma species in different concentrations were also tested. RESULTS: In total 5269 patients were included. The prevalence of MG was 7.2% (382/5269; 4.9-9.8% in the countries). The sensitivity of the CE/IVD AMG, MG Alt TMA-1 and mgpB qPCR ranged 99.13-100%, 99.13-100% and 73.24-81.60%, respectively, in the countries. The specificity ranged 99.57-99.96%, 100% and 99.69-100%, respectively. The prevalence of resistance-associated mutations for azithromycin and moxifloxacin was 41.4% (120/290; 17.7-56.6%) and 6.6% (18/274; 4.1-10.2%), respectively. Multidrug resistance was found in all countries (2.7%; 1.1-4.2%). CONCLUSIONS: Both transcription-mediated amplification (TMA)-based MG assays had a highly superior sensitivity compared to the mgpB qPCR. The prevalence of MG and azithromycin resistance was high. Validated and quality-assured molecular tests for MG, routine resistance testing of MG-positive samples and antimicrobial resistance surveillance are crucial.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Unemo M, Salado-Rasmussen K, Hansen M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect. 2017. PMID: 28923377. doi:10.1016/j.cmi.2017.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。